pyrazines has been researched along with Lymphoma, Large B-Cell, Diffuse in 44 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (29.55) | 29.6817 |
| 2010's | 26 (59.09) | 24.3611 |
| 2020's | 5 (11.36) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, JR; Byrd, JC; Cheung, J; Eyre, TA; Furman, RR; Ghia, P; Hamdy, A; Hillmen, P; Izumi, R; Pagel, JM; Patel, P; Schuh, A; Wang, MH; Wierda, WG; Xu, Y | 1 |
| Al-Sawaf, O; Fischer, K | 1 |
| Hiramoto, M; Hirano, M; Kaneko, N; Koshio, H; Matsuya, T; Mori, M; Sakagami, H; Takeuchi, M; Tanaka, H; Yamanaka, Y | 1 |
| Junghanss, C; Kong, W; Murua Escobar, H; Nolte, I; Perez, SV; Ruetgen, B; Sekora, A; Sender, S | 1 |
| Calvo, R; De Vos, S; Dyer, MJS; Flowers, CR; Frigault, MM; Maddocks, KJ; Patel, P; Ruan, J; Rule, S; Strati, P; Wei, H; Xu, Y | 1 |
| Assouline, S; Burke, JM; Chen, R; Essell, J; Patel-Donnelly, D; Sharman, J; Shi, W; Shustov, A; Yang, J; Ye, W | 1 |
| Alhalouli, T; Bueso-Ramos, C; Burger, J; Estrov, Z; Ferrajoli, A; Jain, N; Jain, P; Kanagal-Shamanna, R; Kantarjian, HM; Keating, M; Khoury, JD; Luthra, R; Medeiros, LJ; Patel, KP; Routbort, M; Wierda, W | 1 |
| Appleby, N; Boucher, R; Cabes, M; Eyre, TA; Fox, S; Hillmen, P; Jackson, A; Rawstron, A; Schuh, A; Yates, F | 1 |
| Bernasconi, E; Bertoni, F; Cascione, L; Dirnhofer, S; Gaudio, E; Gerlach, MM; Mascia, M; Priebe, V; Spriano, F; Stathis, A; Tarantelli, C; Targa, A; Zucca, E | 1 |
| Ahmed, M; Al-Kuraya, KS; Al-Obaisi, KA; Bu, R; Hussain, AR; Uddin, S | 1 |
| Colvin, J; Evens, AM; Gordon, LI; Helenowski, I; Kline, J; Larsen, A; Rosen, ST; Smith, SM; van Besien, KM; Winter, JN | 1 |
| Wang, ZQ; Xie, JL; Zhou, XG | 1 |
| Alvarez, R; Cabeçadas, J; Calaminici, M; Clear, AJ; Coutinho, R; Gomes da Silva, M; Gribben, JG; Lee, A; Matthews, J; Owen, A; Wilson, A | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Cao, C; Kai, S; Liu, T; Wang, L; Xiang, B; Zhu, H | 1 |
| Castillo, JJ; Reagan, JL; Sikov, WM; Winer, ES | 1 |
| Demosthenous, C; Dogan, A; Gupta, M; Han, JJ; Hege, K; Link, B; Maurer, MJ; Sotomayor, E; Stenson, MJ; Wellik, LE; Witzig, T | 1 |
| Byrd, JC; Coombes, KR; Coss, CC; Covey, T; Gardner, HL; Gulrajani, M; Hamdy, A; Harrington, BK; Izumi, R; Johnson, AJ; Kaptein, A; Kisseberth, WC; Krejsa, C; London, CA; Rothbaum, W; Russell, DS; Urie, BK; Van Lith, B; Zhang, X | 1 |
| Bhagat, G; Furman, RR; Gardner, JR; Gonen, M; Gueorguiev, VD; Heaney, ML; Manova, K; O'Connor, OA; Paoluzzi, L; Scotto, L | 1 |
| Barrientos, J; Elstrom, R; Leonard, JP; Martin, P | 1 |
| Ahmed, M; Ajarim, D; Al-Dayel, F; Al-Kuraya, KS; Bavi, P; Belgaumi, A; Hussain, A; Uddin, S | 1 |
| Chaganti, RS; Houldsworth, J; Olshen, AB; Petlakh, M | 1 |
| Bose, P; Gandhi, D; Ghabach, B; Ozer, H; Thompson, C | 1 |
| Dasmahapatra, G; Dent, P; Fisher, RI; Friedberg, J; Grant, S; Kramer, L; Lembersky, D; Rahmani, M | 1 |
| Czuczman, MS; Dave, SS; Dunleavy, K; Grant, N; Jaffe, ES; Janik, JE; Pittaluga, S; Shovlin, M; Staudt, LM; Wilson, WH; Wright, G | 1 |
| Hertan, LM; Koumenis, C | 1 |
| Dasmahapatra, G; Dent, P; Fisher, RI; Friedberg, J; Grant, S; Kramer, L; Lembersky, D | 1 |
| Guo, H; Mao, J; Sun, C; Wang, J; Zhou, X | 1 |
| Cheung, YK; Coleman, M; Elstrom, R; Furman, RR; LaCasce, AS; Leonard, JP; Martin, P; Ruan, J; Vose, JM | 1 |
| Carbone, A; Gloghini, A; Spina, M; Tirelli, U | 1 |
| Cesarman, E; Chadburn, A; Cheung, K; Coleman, M; Elstrom, R; Ely, S; Furman, RR; Lacasce, A; Lee, SM; Leonard, JP; Martin, P; Morrison, J; Ruan, J; Vose, JM | 1 |
| Dreyling, M | 1 |
| Bhagat, G; Bongero, D; Lipstein, M; Montanari, F; O'Connor, O; Paoluzzi, L | 1 |
| Campo, E; Colomer, D; Jares, P; López-Guillermo, A; Martinez, A; Mozos, A; Roué, G | 1 |
| Andemariam, B; Coleman, M; Elstrom, RL; Furman, RR; Leonard, JP; Martin, P; Ruan, J; Shore, TB | 1 |
| Ahmed, M; Al-Dayel, F; Al-Kuraya, KS; Bavi, P; Hussain, AR; Siddiqui, K; Uddin, S | 1 |
| Cabanillas, F | 1 |
| Bauer, F; Codreanu, I; Dasanu, CA; Padmanabhan, P; Rampurwala, M | 1 |
| Dasmahapatra, G; Dent, P; Fisher, RI; Friedberg, J; Grant, S; Patel, H | 1 |
| Schenkein, D | 1 |
| Bohlius, J; Engert, A; Hülsewede, H; Kober, T | 1 |
| Anderson, KC; Bhole, D; Burger, R; Catley, L; Chauhan, D; Galardy, P; Hideshima, T; Kessler, B; Mitsiades, C; Munshi, NC; Ploegh, H; Podar, K; Shringarpure, R; Tai, YT; Tassone, P | 1 |
| Basso, G; Bonvini, P; Rosolen, A; Zorzi, E | 1 |
6 review(s) available for pyrazines and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Duodenum; Epirubicin; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Pyrazines; Remission Induction; Stomach; Thalidomide; Tomography, X-Ray Computed; Vincristine | 2014 |
Targeted treatment and new agents in diffuse large B-cell lymphoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Delivery Systems; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Inhibitor of Apoptosis Proteins; Lymphoma, Large B-Cell, Diffuse; Microtubule-Associated Proteins; Neoplasm Proteins; Protease Inhibitors; Protein Kinases; Pyrazines; Survivin; TOR Serine-Threonine Kinases; Treatment Outcome; Vorinostat | 2008 |
Therapeutic options for HIV-associated lymphomas.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Boronic Acids; Bortezomib; Epstein-Barr Virus Infections; HIV Infections; Humans; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Pyrazines; Rituximab; Treatment Outcome | 2010 |
[Malignant lymphoma: individualized treatment according to biological and clinical risk factors].
Topics: Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Ki-1 Antigen; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Precision Medicine; Prognosis; Pyrazines; Risk Factors; Rituximab; Survival Rate; Waldenstrom Macroglobulinemia | 2011 |
Proteasome inhibitors in the treatment of B-cell malignancies.
Topics: Acetylcysteine; Animals; Boronic Acids; Bortezomib; Cell Cycle Proteins; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzymes; Gene Expression Regulation; Hodgkin Disease; Humans; Leukemia, B-Cell; Leupeptins; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mice; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; Oncogene Proteins; Peptide Hydrolases; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Substrate Specificity; Transcription Factors; Treatment Outcome | 2002 |
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Europe; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Multicenter Studies as Topic; Multiple Myeloma; National Institutes of Health (U.S.); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Procarbazine; Pyrazines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; United States; Vinblastine; Vincristine | 2006 |
9 trial(s) available for pyrazines and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2021 |
Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Lymphoma, Large B-Cell, Diffuse; Pyrazines | 2021 |
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Female; Humans; Indazoles; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Syk Kinase; Time Factors | 2018 |
The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Prospective Studies; Pyrazines; Recurrence; Research Design; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2019 |
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Pyrazines; Recurrence; Treatment Outcome | 2013 |
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Anorexia; Antineoplastic Agents; B-Lymphocytes; Benzamides; Cell Line, Tumor; Diarrhea; Disease Models, Animal; Disease-Free Survival; Dogs; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Humans; Lethargy; Lymphoma, Large B-Cell, Diffuse; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Vomiting; Weight Loss | 2016 |
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Pyrazines; Rituximab; Vincristine | 2010 |
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Pyrazines; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2011 |
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Etoposide; Humans; Ifosfamide; Immunotherapy; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Proteasome Endopeptidase Complex; Pyrazines; Recurrence; Rituximab; Time Factors; Treatment Outcome | 2012 |
29 other study(ies) available for pyrazines and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Acalabrutinib monotherapy in patients with Richter transformation.
Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Pyrazines | 2021 |
Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; B-Lymphocytes; Cells, Cultured; Female; Humans; Lymphocyte Activation; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Transgenic; Piperazines; Piperidines; Pyrazines; Pyrrolidines; Receptors, Antigen, B-Cell; Xenograft Model Antitumor Assays | 2020 |
Pan- and Isoform-specific Inhibition of the Bromodomain and Extra-terminal Proteins and Evaluation of Synergistic Potential With Entospletinib in Canine Lymphoma.
Topics: Animals; Cell Line, Tumor; Dogs; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 4 or More Rings; Indazoles; Lymphoma, Large B-Cell, Diffuse; Nuclear Proteins; Piperazines; Protein Isoforms; Protein Serine-Threonine Kinases; Pyrazines; Pyrazoles; Pyridazines; Syk Kinase | 2020 |
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cell Transformation, Neoplastic; Cohort Studies; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mutation; Piperidines; Prognosis; Pyrazines; Pyrazoles; Pyrimidines | 2019 |
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.
Topics: Adenosine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mice, SCID; Protein Kinase Inhibitors; Pyrazines; Quinolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Flow Cytometry; Humans; I-kappa B Proteins; Immunoblotting; Inhibitor of Apoptosis Proteins; Lymphoma, Large B-Cell, Diffuse; Mitochondria; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Proteasome Endopeptidase Complex; Proteolysis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Survivin; X-Linked Inhibitor of Apoptosis Protein | 2014 |
[Right cervical lymph node enlargement].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclin D1; Dexamethasone; Diagnosis, Differential; Follow-Up Studies; Histiocytic Necrotizing Lymphadenitis; Humans; Infectious Mononucleosis; Ki-67 Antigen; Lymph Nodes; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Middle Aged; Neck; Pyrazines; SOXC Transcription Factors | 2013 |
Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Boronic Acids; Bortezomib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Pathology, Molecular; Prognosis; Pyrazines | 2013 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Etoposide; Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Positron-Emission Tomography; Prednisone; Pyrazines; Treatment Outcome; Vincristine | 2015 |
Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Topics: Adaptor Proteins, Signal Transducing; Cell Cycle Proteins; Cell Line, Tumor; Cyclin D3; Eukaryotic Initiation Factor-4E; Eukaryotic Initiation Factor-4F; Eukaryotic Initiation Factor-4G; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Imidazoles; Lymphoma, Large B-Cell, Diffuse; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Phosphoproteins; Phosphorylation; Protein Biosynthesis; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-myc; Pyrazines; RNA Caps; RNA Interference; RNA, Neoplasm; RNA, Small Interfering; TOR Serine-Threonine Kinases; Tumor Stem Cell Assay | 2015 |
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Health; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Membrane Potential, Mitochondrial; Mice; Microscopy, Confocal; Molecular Mimicry; Nitrophenols; Piperazines; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; Tissue Donors; Xenograft Model Antitumor Assays | 2008 |
S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Pyrazines; RNA, Small Interfering; S-Phase Kinase-Associated Proteins | 2008 |
Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response.
Topics: Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Doxorubicin; Drug Resistance; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Large B-Cell, Diffuse; NF-kappa B; Prognosis; Pyrazines; Systems Biology; Tumor Suppressor Protein p53 | 2008 |
AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib.
Topics: Adult; Boronic Acids; Bortezomib; Humans; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Male; Pyrazines; Remission Induction; Shock, Septic | 2009 |
Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Enzyme Activation; Enzyme Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; Lymphoma, Large B-Cell, Diffuse; Nitriles; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction | 2009 |
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Tumor; Boronic Acids; Bortezomib; Doxorubicin; Female; Gene Expression Profiling; Germinal Center; Humans; Immunoenzyme Techniques; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Prognosis; Pyrazines; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Piling up the JNK: drug synergy through ER stress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Boronic Acids; Bortezomib; Drug Synergism; Endoplasmic Reticulum; Enzyme Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; Lymphoma, Large B-Cell, Diffuse; Nitriles; Protease Inhibitors; Pyrazines; Signal Transduction | 2009 |
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Chymotrypsin; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; In Vitro Techniques; JNK Mitogen-Activated Protein Kinases; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Nude; Mitochondria; NF-kappa B; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Vorinostat; Xenograft Model Antitumor Assays | 2010 |
Rapid fatal pulmonary complications in a Chinese patient after bortezomib treatment for ALK-negative anaplastic large-cell lymphoma.
Topics: Aged; Asian People; Boronic Acids; Bortezomib; Enzyme Inhibitors; Fatal Outcome; Hematologic Neoplasms; Humans; Lung; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Male; Pyrazines | 2010 |
Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; HIV Infections; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Pyrazines; Tumor Lysis Syndrome | 2010 |
The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclophosphamide; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Protease Inhibitors; Pyrazines; Receptors, Neuropeptide; RNA, Messenger; RNA, Small Interfering; Survival Analysis; Treatment Outcome; Unfolded Protein Response; Vincristine; Young Adult | 2011 |
Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Movement; Forkhead Box Protein M1; Forkhead Transcription Factors; Gene Expression; Humans; Immunohistochemistry; Ki-67 Antigen; Lymphoma, Large B-Cell, Diffuse; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Molecular Targeted Therapy; Primary Cell Culture; Proliferating Cell Nuclear Antigen; Pyrazines; RNA, Small Interfering; S-Phase Kinase-Associated Proteins; Signal Transduction; Thiostrepton; Tumor Stem Cell Assay | 2012 |
New developments in the field of diffuse large cell lymphoma.
Topics: Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Breast Implants; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Pyrazines | 2012 |
Plasmablastic haemato-lymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib.
Topics: Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Burkitt Lymphoma; Fatal Outcome; Genes, myc; Herpesvirus 4, Human; Humans; Immunoglobulin M; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasms, Second Primary; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrazines; Retroperitoneal Neoplasms; Transcriptome; Translocation, Genetic | 2013 |
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mitochondria; NF-kappa B; Piperidines; Proteasome Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrazoles; Pyrimidines; Reactive Oxygen Species; Tumor Cells, Cultured | 2013 |
Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Polymerase Chain Reaction; Proteasome Inhibitors; Pyrazines; TCF Transcription Factors; Transcription Factor 7-Like 2 Protein; Tumor Cells, Cultured | 2006 |
Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Division; Cell Line, Tumor; Enzyme Inhibitors; G2 Phase; Humans; Lymphoma, Large B-Cell, Diffuse; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2007 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |